A slides set on RA Treatment options with MTX teaching slides
Pivotal Trials in at-risk patients.
The pros and cons of Private Practice vs. Academic Medicine. - submitted by Kathryn Dao, MD
Distinguishing features between the 2021 ACR and 2022 EULAR RA treatment guidelines
Oral Surveillance study resulted in a new FDA drug safety bulleting 9/21/21 and since the label for all JAK inhibitors has changed (FDA, Canada) or will change (EMA).
Use this resource to keep track of your clinical trials and key information needed when communicating with patients about a drug study.
Outcomes, misdiagnosis, diagnosis, Diagnostic criteria and treatmenet options for AOSD
Overview of the definition, demographics, epidemiology, and presenting features of AOSD